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Daniel S. Sax, M . D . (left), professor of neurology at B U S M , questions Field Effects president Ronald Hol-
singer about aspects of new M R I instrument as Dr. Green looks on. Instrument, currently in development 
at Field Effects' Acton, Mass., facility, is to be installed in University Hospital early next year. Permanent 
magnet ring, main element of scanner, is made of cobalt-samarium and weighs five tons. 
MRI technology, no longer 
experimental, is proving 
its clinical usefulness 
Magnetic resonance imaging (MRI), in its in-
fancy just five years ago, now stands ready to 
become a major contributor to clinical medi-
cine. 
That's the assessment of Allan M . Green, 
M.D., Ph.D., head of the Evans Section of 
Nuclear Medicine and director of the new 
University Hospital/Boston City Hospital 
Joint Facility for Magnetic Resonance Imag-
ing. 
According to Dr. Green, one primary goal 
of the JFMRI w i l l he to help develop new 
uses, and more sophisticated applications of 
existing uses, for magnetic resonance imag-
ing. 
"Of particular interest are applications re-
lated to head-and-neck trauma, neurologic 
disorders, cardiac muscle metabolism and 
the identification of malignant disease," he 
says, adding that he and his associates w i l l 
he collaborating wi th other BCH and U H 
staff members in exploring these areas. 
The Joint Facility is scheduled to he in op-
eration by early next year. To he housed in 
the basement of the Evans Building, i t w i l l 
provide physicians at the sponsoring hospi-
tals wi th important new diagnostic capabili-
ties, ranging from the ability to identify oth-
erwise elusive lesions of the brain to the 
power to localize disorders of the bone and 
soft tissues wi th great specificity. 
The instrument that makes such achieve-
ments possible is manufactured by Field 
Effects, Inc., of Acton, Mass., and is the first 
in the nation to feature a rare-earth perma-
nent magnet rather than a superconductive 
magnet. 
The decision to choose an instrument wi th 
a rare-earth permanent magnet was made 
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'Metastatic tumors in 
the liver show up like 
tiny little BBs against 
the bright background 
of the normal tissue.' 
MRI technology... 
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after extensive investigations of both types of 
MRI units by Dr. Green and other U H and 
BCH staff members. "Our decision does not 
mean that we think superconducting instru-
ments are less effective," says Dr. Green, 
"but we concluded that the rare-earth perma-
nent magnet has significant technological 
and financial advantages." 
One of the advantages is that the magnetic 
field is contained entirely within the instru-
ment, so there is no need for the extensive, 
and expensive, protective shielding required 
in the walls of the rooms housing MRI units 
wi th superconductive magnets. Another ad-
vantage, related to the first, is that the cost 
of the permanent-magnet unit is a third to a 
half less than that of the traditional types of 
instruments. 
Differentiating soft tissues 
The key to MRI's diagnostic value is that 
the technology allows users to distinguish 
among different types of soft tissues based on 
chemical differences. Combined wi th the 
fact that its signals readily penetrate bone, 
that feature makes i t an ideal instrument for 
diagnosing certain hrain lesions. 
"Right now, MRI is the diagnostic ap-
proach of choice for posterior-fossa and 
medullary-cervical junction lesions," says Dr. 
Green, "because these are not seen very well 
C T scan (left) and M R I scan show approximately same transverse plane of pa-
tient's brain. Both images demonstrate enlargement of ventricles resulting from 
brainstem infarct. M R I also provides detail of brain folds, however, demonstrating 
its ability to depict soft tissue structures. C T scan required use of contrast fluids, 
but not M R I scan. 
by other imaging techniques." 
MRI also is useful in diagnosing a range of 
other nervous-system conditions, including 
multiple sclerosis. And it's effective, as well, 
in diagnosing tumors in certain other organs, 
notably the liver. 
"The liver has a lot of fatty material, hut 
tumors contain very little fat," says Dr. 
Green. "That means metastatic tumors in 
the liver show up like tiny little BBs against 
the bright background of the normal tissue." 
Despite having proven its value for a vari-
ety of conditions, MRI's usefulness has been 
limited by the time i t takes to perform 
scans. Since a typical scan involves generat-
ing images of 15 "slices," and each one takes 
a minute or more, significant movement of 
the body or the target organ can result in im-
ages too blurry to be clinically useful. 
Various techniques, however, are helping 
to overcome that problem. Computer "gat-
ing" of images is a key innovation. Measure-
ments of the nuclear transmissions rrom, 
say, the heart are timed to the heartbeat. The 
result is that the heart structures being 
scanned are in the same position each time 
the transmission is measured, eliminating 
the problem of heart-motion interference 
wi th the image. 
Adding to the technology's value in cardio-
vascular studies is the fact that movement 
makes the blood a natural contrast medium 
in MRI scanning. Since the instrument scans 
narrow planes through the body, the blood's 
motion means that the MRTstimulated 
atoms have already gone past the imaging 
plane when their signals are emitted. The re-
sult is that the scanner won't pick up any 
signals from the blood. 
A new look at the heart 
Cardiovascular applications are a major in-
terest of Dr. Green's. For example, he plans 
to collaborate w i t h cardiologists from U H 
and BCH in assessing the new technology's 
value in diagnosing heart-muscle conditions. 
"Chronic hypertension and severe athero-
sclerotic disease produce changes in the me-
tabolism of the heart muscle," he notes. 
"These may involve either scarring or the 
deposition of fat, both of which can be seen 
very accurately wi th MRI . " 
So far, magnetic resonance imaging of re-
gions like the upper and middle GI tract 
doesn't appear feasible. The technology is ef-
fective, however, in diagnosing lesions of the 
lower GI tract and some reproductive organs. 
Their location within the complex bony 
structure of the pelvis minimizes the prob-
lems associated wi th body movement. 
Diagnosing hone lesions 
MRI is also increasingly useful in diagnos-
ing lesions of the bone and connective tissue. 
For example, while i t doesn't generate clini-
cally useful images of hone calcium, i t can 
distinguish between normal and diseased 
marrow. 
The technology also is proving itself in the 
diagnosis of hone conditions that affect at-
tached muscles and ligaments. Dr. Green 
cites the example of the jogger with a bone 
spur that has produced inflammation in 
nearby tissues, and is causing the victim 
much pain. 
"Using so-called surface coils to record 
MRI signals, which allow you to get very 
high-resolution images of small parts of the 
body," he says, "you can see the extent of 
inflammation in muscle and ligament in ex-
quisite detail." • 
New dermatology chief 
conducts research at the 
bench and in the clinic 
Barbara A. Gilchrest, M.D., has spent the 
past several years performing that most diffi-
cult of juggling acts: carrying on both clini-
cal and basic research while at the same 
time maintaining an active practice. 
It's a career that has yielded some impres-
sive dividends for Dr. Gilchrest, who re-
cently became chief of dermatology at 
' UH. She's nationally known for her innova-
tive work in the laser treatment of port-wine 
stains, and has helped many patients with 
such stains to escape the high social and psy-
chological costs the disfigurements often 
carry. In the basic-research realm, she has, 
among other achievements, helped to iden-
tify new skin-cell growth factors. 
Hers also is a career that in no sense 
emerged from any master plan. " I just hap-
pened to he in certain places where certain 
things were going on, and I guess fate took 
over from there," says Dr. Gilchrest, who 
also has been named professor and chairman 
of BUSM's Department of Dermatology. 
In any case, she doesn't regret the way 
things have turned out. "It's wonderful when 
someone w i t h an M.D. is able to find an in-
terest that spans the bench and the clinic," 
she says. 
Studies of skin aging 
The new dermatology chief comes to Bos-
ton University Medical Center from the Hu-
man Nutri t ion Research Center on Aging at 
Tufts University and the New England Medi-
cal Center. Prior to that, from 1977 to 1983, 
she was at the Beth Israel Hospital and Har-
vard Medical School. (She's a I97I graduate 
of that school.) 
Dr. Gilchrest's chief basic research interest 
is in cellular aspects of skin aging. In pursuit 
of this interest, she and her associates have 
created serum-free systems that allow for 
tightly controlled nurturing of different skin 
cells in culture. It was from their quest for 
such systems that die discoveries about 
growth factors emerged. 
"We were using bovine hypothalamus as 
one supplement for cells in culture," notes 
Dr. Gilchrest, "and we discovered that i t 
contains growth factors for both keratino-
cytes, which are the main component of the 
epidermis, and melanocytes." 
Probing immune-function losses 
With the help of the new culture systems. 
Dr. Gilchrest and her co-workers have been 
exploring the impact on cells of skin aging. 
One series of experiments disclosed that 
cells from sun-exposed areas have shorter life 
spans than non-exposed cells from the same 
donor. Another series turned up a possible 
clue to the loss of immune function that 
goes with aging. 
"Epidermal-derived thymocyte-activating 
factor is a mediator very similar to interleu-
kin 2 that was first discovered in lympho-
Dr. Gilchrest chats with patient who is due for laser treatment of skin lesion. 
cytes and that has a series of specific im-
mune functions," she notes. "ETAF is also 
produced by keratinocytes, and we discov-
ered that the keratinocyte production of the 
mediator in culture declines wi th the age of 
the cell donor." 
Treating port-wine stains 
On the clinical side. Dr. Gilchrest's main 
research interest is modifying the laser so as 
to minimize the risk of scarring in the treat-
ment of port-wine stains. 
The argon laser has been used to treat such 
stains for several years, w i t h generally good 
results. In more than 90 percent of patients, 
the discoloration is largely eliminated. In 
some cases, though, the treatment produces 
an unsightly scar. The problem is especially 
severe in children. Roughly a quarter of the 
youngsters wi th port-wine stains treated 
with the laser have wound up wi th serious 
scars. 
The scarring phenomenon has kept most 
dermatologists from treating children. Yet i t 
is as children that many bearers of port-wine 
stains face the most difficult social stigma. 
Strong parental reactions 
"Parents often have very strong reactions, 
ranging from horror to anger to guilt, when a 
child is horn wi th a lasting port-wine stain," 
she says. "And studies have shown that as 
soon as a child has any self-awareness—often 
as early as the end of their first year—they 
become aware that they're different." The 
cumulative impact of the negative reactions 
of parents and others over the years may be 
permanent damage to a child's self-esteem. 
The laser modification, developed by two 
Boston-area physicists and clinically tested 
by Dr. Gilchrest and her associates, involves 
rotating the laser tip at 1,400 rpm. The result 
is that no one skin area is exposed to the 
laser beam for more than a millisecond—too 
short a time for the laser-generated heat to 
spread from the blood vessels that are its tar-
Continued on page 4 
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Noteworthy 
Two new staff members have been appointed 
to Evans positions in recent months. They 
are: 
Dennis M. DiSorbo, Ph.D., special scien-
tific member of the Evans Section of Medical 
Oncology. Dr. DiSorho previously was a staff 
member at Nassau Hospital on Long Island 
and an assistant professor of medicine at the 
State University of New York (SUNY) at 
Stony Brook. He received his doctorate in 
biochemistry from the Roswell Park Memo-
rial Institute at the SUNY Buffalo, and did 
postdoctoral work at the Eels Research Insti-
tute of Temple University School of Medi-
cine in Philadelphia. He also has been ap-
pointed an assistant professor of medicine at 
BUSM. 
George Triadafilopoulos, M.D., Section of 
Gastroenterology. Dr. Triadafilopoulos is a 
graduate of the Aristotlean University of 
Thessaloniki Medical School, Thessaloniki, 
Greece. His residency training was at hospi-
tals affiliated wi th Wayne State University in 
Detroit. Prior to his present appointment, he 
held a gastroenterology fellowship at Boston 
University Medical Center. Dr. Triadafilo-
poulos also has been appointed as a staff gas-
troenterologist in the University Hospital 
Department of Medicine and as an instructor 
in medicine at BUSM. • 
Dermatology chieL. 
Continued from page 3 
get to surrounding connective tissues and 
produce scarring. 
"We've only been using the modification 
for a short time, so we don't have definitive 
results," says Dr. Gilchrest, "hut we've tried 
i t in a variety of patients, including some 
children, w i t h good success, and that's very 
exciting." • 
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Evans/Transition 
A total of 13 Evans members completed their 
University Hospital residencies earlier this 
year. The graduates, and their present pur-
suits, are: 
Dan Berlowitz, M.D., general medicine fel-
lowship, University Hospital. 
Stephen Bresnahan, M.D., private practice, 
Abingdon, Mass. 
Mike Czorniak, M.D., pulmonary fellowship. 
University Hospital. 
Paul Demchak, M.D., hematology/oncology 
fellowship. New England Medical Center. 
Lionel Faitelson, M.D., cardiology fellowship, 
Baylor University, Houston, Tex. 
Mitchell Fogel, M.D., renal fellowship. Uni-
versity Hospital. 
Kamran Ghalili, M.D,, chief resident. Uni-
versity Hospital. 
Raphael Kieval, M.D., rheumatology fellow-
ship, Brigham and Women's Hospital. 
Laurie Letvak, M.D., hematology/oncology 
fellowship. New York University. 
Rosemary Mehl, M.D., hematology/oncology 
fellowship, Massachusetts General Hospi-
tal. 
Larry Moschitto, M.D., cardiology fellow-
ship. University Hospital. 
David Polakoff, M.D., geriatrics fellowship, 
Bedford Veterans Administration Medical 
Center. 
Steven Sepe, M.D., private practice, Cran-
ston, R.I. 
The new Evans trainees, and the medical 
schools from which they graduated, are: 
Manuel Anton, M.D., Emory University. 
Mary Lou Ashur, M.D., University of Con-
necticut. 
Andrew Chodos, M.D,, Albany Medical Col-
lege. 
Phyllis Croke, M.D., University of Pennsyl-
vania. 
Helene Fischer, M.D., Cornell University. 
Peter Francis, M.D., New York University. 
Russell Gerry, M.D., University of Connecti-
cut. 
Eric Manning, M.D., University of California 
at Davis. 
Joanne Murabito, M.D., Mount Sinai. 
Margaret O'Donoghue, M.D., Johns Hopkins. 
Robert Peterfreund, M.D., University of Cali-
fornia at San Diego. 
Kenneth Silverstein, M.D., New York Uni-
versity. 
Alan Steele, M.D., Boston University. 
Kenneth Steinberg, M.D., New York Medical 
College. 
Richard Taikowski, M.D., Boston University. 
Robert Weiss, M.D., Columbia University. 
Anthony White, M.D., Case Western Reserve 
University. • 
